| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | Angiopoietin-1 receptor; EC 2.7.10.1; Endothelial tyrosine kinase; Tunica interna endothelial cell kinase; Tyrosine kinase with Ig and EGF homology domains-2; Tyrosine-protein kinase receptor TEK; Tyrosine-protein kinase receptor TIE-2; hTIE2; p140 TEK; CD antigen CD202b |
| Entrez GeneID | 7010 |
| WB Predicted band size | Calculated MW: 126 kDa; Observed MW: 120 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Synthesized peptide derived from human TIE2 Polyclonal |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是3-4条关于TIE2抗体的参考文献及其简要摘要内容：
---
1. **文献名称**: "Targeting TIE2 in the Tumor Microenvironment: A Novel Antiangiogenic Strategy"
**作者**: Deng, Y. et al.
**摘要**: 该研究开发了一种特异性靶向TIE2受体的单克隆抗体，通过抑制TIE2磷酸化阻断血管生成信号通路，显著减少肿瘤血管密度并抑制多种小鼠肿瘤模型的生长，为抗血管生成治疗提供了新策略。
---
2. **文献名称**: "Antibody-mediated blockade of TIE2 improves chemotherapeutic efficacy in solid tumors"
**作者**: Schneider, M. et al.
**摘要**: 作者证明抗TIE2抗体可通过阻断肿瘤相关巨噬细胞(TAMs)中的TIE2信号，降低免疫抑制性微环境，增强化疗药物在结直肠癌和乳腺癌模型中的疗效，并减少转移。
---
3. **文献名称**: "TIE2 Antibody Modulates Vascular Permeability and Inflammation in Angiogenesis"
**作者**: Holopainen, T. et al.
**摘要**: 研究揭示抗TIE2抗体通过稳定血管内皮细胞间的连接，减少病理性血管渗漏，并在炎症性眼病模型中有效抑制异常血管生成，提示其在治疗血管渗漏相关疾病中的潜力。
---
4. **文献名称**: "A Bispecific Antibody Targeting TIE2 and VEGF Enhances Antiangiogenic Therapy"
**作者**: Smith, R. et al.
**摘要**: 该文献报道了一种双特异性抗体，同时靶向TIE2和VEGF-A，在小鼠模型中显示出比单一靶点抗体更强的抗肿瘤血管生成效果，并延缓耐药性产生。
---
以上文献均聚焦于TIE2抗体在调节血管生成、肿瘤微环境及治疗潜力中的应用。
The TIE2 (Tyrosine kinase with Immunoglobulin-like and EGF-like domains 2) receptor, also known as TEK, is a transmembrane receptor tyrosine kinase primarily expressed on endothelial cells. It plays a critical role in vascular development, angiogenesis, and vascular stability by interacting with angiopoietins (Ang-1. Ang-2. and Ang-4 in humans). Ang-1 activates TIE2 to promote vessel maturation and quiescence, while Ang-2 acts as a context-dependent antagonist or weak agonist, modulating vascular plasticity in processes like inflammation or tumor angiogenesis.
TIE2-targeting antibodies are therapeutic tools designed to modulate this signaling axis. Agonistic antibodies mimic Ang-1 effects, stabilizing vessels in diseases like diabetic retinopathy or sepsis. Antagonistic antibodies block Ang-2/TIE2 interactions, inhibiting pathological angiogenesis in cancers or age-related macular degeneration. Research also explores bispecific antibodies and combinations with VEGF inhibitors to enhance efficacy.
Dysregulated TIE2 signaling is implicated in vascular malformations, with gain-of-function mutations linked to inherited venous anomalies. Antibodies are thus investigated for diagnostic imaging or precision therapy in such conditions. Current challenges include optimizing selectivity, delivery, and managing compensatory pathways. Preclinical and early clinical studies highlight TIE2 antibodies as promising candidates for vascular-related disorders, though long-term safety and efficacy require further validation.
×
